<?xml version='1.0' encoding='utf-8'?>
<document id="20680253"><sentence text="Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam."><entity charOffset="93-102" id="DDI-PubMed.20680253.s1.e0" text="midazolam" /></sentence><sentence text="Midazolam metabolic clearance to 1'-hydroxymidazolam is an accurate measure of CYP3A activity which requires extensive plasma and urine sampling"><entity charOffset="0-9" id="DDI-PubMed.20680253.s2.e0" text="Midazolam" /><entity charOffset="33-52" id="DDI-PubMed.20680253.s2.e1" text="1'-hydroxymidazolam" /><pair ddi="false" e1="DDI-PubMed.20680253.s2.e0" e2="DDI-PubMed.20680253.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20680253.s2.e0" e2="DDI-PubMed.20680253.s2.e1" /></sentence><sentence text=" The objective of this study was to find a new limited sampling strategy (LSS) to predict midazolam metabolic clearance to 1'-hydroxymidazolam and subsequently CYP3A activity in an easy and reliable way, reducing costs and labour"><entity charOffset="123-142" id="DDI-PubMed.20680253.s3.e0" text="1'-hydroxymidazolam" /></sentence><sentence text="" /><sentence text="The development of this LSS is based on data from an in vivo drug-drug interaction study carried out in our clinical research unit" /><sentence text=" Various partial AUCs of midazolam were calculated and correlated with metabolic clearance of midazolam to 1'-hydroxymidazolam by non-linear regression"><entity charOffset="25-34" id="DDI-PubMed.20680253.s6.e0" text="midazolam" /><entity charOffset="94-103" id="DDI-PubMed.20680253.s6.e1" text="midazolam" /><entity charOffset="107-126" id="DDI-PubMed.20680253.s6.e2" text="1'-hydroxymidazolam" /><pair ddi="false" e1="DDI-PubMed.20680253.s6.e0" e2="DDI-PubMed.20680253.s6.e0" /><pair ddi="false" e1="DDI-PubMed.20680253.s6.e0" e2="DDI-PubMed.20680253.s6.e1" /><pair ddi="false" e1="DDI-PubMed.20680253.s6.e0" e2="DDI-PubMed.20680253.s6.e2" /><pair ddi="false" e1="DDI-PubMed.20680253.s6.e1" e2="DDI-PubMed.20680253.s6.e1" /><pair ddi="false" e1="DDI-PubMed.20680253.s6.e1" e2="DDI-PubMed.20680253.s6.e2" /></sentence><sentence text=" The correlation with highest r (2) values was chosen to predict the midazolam metabolic clearance"><entity charOffset="69-78" id="DDI-PubMed.20680253.s7.e0" text="midazolam" /></sentence><sentence text=" Statistical significance of this method was verified by calculating the 95% confidence interval of the differences (%) between predicted and measured metabolic clearance of midazolam to 1'-hydroxymidazolam"><entity charOffset="174-183" id="DDI-PubMed.20680253.s8.e0" text="midazolam" /><entity charOffset="187-206" id="DDI-PubMed.20680253.s8.e1" text="1'-hydroxymidazolam" /><pair ddi="false" e1="DDI-PubMed.20680253.s8.e0" e2="DDI-PubMed.20680253.s8.e0" /><pair ddi="false" e1="DDI-PubMed.20680253.s8.e0" e2="DDI-PubMed.20680253.s8.e1" /></sentence><sentence text="" /><sentence text="The midazolam partial AUC from 2 to 4 h after oral administration correlated best with metabolic clearance of midazolam to 1'-hydroxymidazolam with r (2)â€‰= 0"><entity charOffset="4-13" id="DDI-PubMed.20680253.s10.e0" text="midazolam" /><entity charOffset="110-119" id="DDI-PubMed.20680253.s10.e1" text="midazolam" /><entity charOffset="123-142" id="DDI-PubMed.20680253.s10.e2" text="1'-hydroxymidazolam" /><pair ddi="false" e1="DDI-PubMed.20680253.s10.e0" e2="DDI-PubMed.20680253.s10.e0" /><pair ddi="false" e1="DDI-PubMed.20680253.s10.e0" e2="DDI-PubMed.20680253.s10.e1" /><pair ddi="false" e1="DDI-PubMed.20680253.s10.e0" e2="DDI-PubMed.20680253.s10.e2" /><pair ddi="false" e1="DDI-PubMed.20680253.s10.e1" e2="DDI-PubMed.20680253.s10.e1" /><pair ddi="false" e1="DDI-PubMed.20680253.s10.e1" e2="DDI-PubMed.20680253.s10.e2" /></sentence><sentence text="9816" /><sentence text=" This partial AUC comprised four midazolam concentrations at 2, 2"><entity charOffset="33-42" id="DDI-PubMed.20680253.s12.e0" text="midazolam" /></sentence><sentence text="5, 3 and 4 h after oral administration of a midazolam solution"><entity charOffset="44-53" id="DDI-PubMed.20680253.s13.e0" text="midazolam" /></sentence><sentence text=" The 95% confidence interval of the differences between predicted metabolic clearance and measured metabolic clearance of midazolam to 1'-hydroxymidazolam was -0"><entity charOffset="122-131" id="DDI-PubMed.20680253.s14.e0" text="midazolam" /><entity charOffset="135-154" id="DDI-PubMed.20680253.s14.e1" text="1'-hydroxymidazolam" /><pair ddi="false" e1="DDI-PubMed.20680253.s14.e0" e2="DDI-PubMed.20680253.s14.e0" /><pair ddi="false" e1="DDI-PubMed.20680253.s14.e0" e2="DDI-PubMed.20680253.s14.e1" /></sentence><sentence text="97 to +13" /><sentence text="2" /><sentence text="" /><sentence text="The determination of the partial AUC using four plasma samples from 2 to 4 h after oral administration of a midazolam solution is proposed to be an easy and reliable CYP3A phenotyping measure which of course needs to be validated in prospective clinical trials"><entity charOffset="108-117" id="DDI-PubMed.20680253.s18.e0" text="midazolam" /></sentence><sentence text="" /></document>